Author + information
- Received March 30, 2017
- Revision received September 26, 2017
- Accepted October 5, 2017
- Published online May 7, 2018.
- Edgard A. Prihadi, MDa,b,
- Victoria Delgado, MD, PhDa,
- Rebecca T. Hahn, MDc,
- Jonathon Leipsic, MDd,
- James K. Min, MDe and
- Jeroen J. Bax, MD, PhDa,∗ ()
- aDepartment of Cardiology, Leiden University Medical Center, Leiden, the Netherlands
- bAntwerp Cardiovascular Center, ZNA Middelheim, Antwerp, Belgium
- cColumbia University Medical Center, New York-Presbyterian Hospital, New York, New York
- dDepartment of Radiology and Division of Cardiology, Centre for Heart Valve Innovation, St Paul's Hospital, University of British Columbia, Vancouver, Canada
- eDepartment of Radiology, The New York-Presbyterian Hospital and the Weill Cornell Medical College, New York, New York
- ↵∗Address for correspondence:
Dr. Jeroen J. Bax, Department of Cardiology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, the Netherlands.
The advent of novel transcatheter therapies for severe tricuspid regurgitation (TR) has attracted much attention. Novel 3-dimensional imaging techniques have permitted analysis of the tricuspid valve (TV) anatomy from unparalleled views and better understanding of the underlying pathophysiology of TR. Grading TR and assessment of right ventricular function remain challenging, and although 2-dimensional echocardiography is the mainstay imaging technique to evaluate patients with severe TR the use of 3-dimensional echocardiography and cardiovascular magnetic resonance is increasing. The number of transcatheter interventions for TR is growing, and procedural success relies significantly on the pre-procedural evaluation of the anatomy of the TV, etiology and severity of TR, right ventricular size and function, and importantly, the anatomic relationships of the TV. The role of multimodality imaging in patient selection and procedural planning for transcatheter TV repair is reviewed.
The Department of Cardiology of the Leiden University Medical Center has received research grants from Edwards Lifesciences, Medtronic, Biotronik, GE Healthcare, and Boston Scientific. Dr. Min is supported by grant UL1TR000457 of the Dalio Institute of Cardiovascular Imaging.
Dr. Delgado has received speaker fees from Abbott Vascular. Dr. Hahn is a speaker for Edwards Lifesciences, Abbott Vascular, Boston Scientific, and GE Medical; is an unpaid national principal investigator for the SCOUT Trial; and is an uncompensated director of Echo Core for multiple industry-sponsored trials. Dr. Leipsic is a consultant for Edwards Lifesciences, Circle CVI, Valtech, and Valcare; and also provides core laboratory services through University of British Columbia to Edwards Lifesciences, Medtronic, Neovasc, and Tendyne. Dr. Min receives research funding from GE Healthcare; serves on the advisory board for Arineta; and has equity interest in Cleerly. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received March 30, 2017.
- Revision received September 26, 2017.
- Accepted October 5, 2017.
- 2018 American College of Cardiology Foundation
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.